Teva Pharmaceutical Industries announced it will acquire Emalex Biosciences for $700 million upfront, with up to $200 million in milestone payments, to gain ecopipam, a first-in-class drug for pediatric Tourette syndrome. Ecopipam, a selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations, showed positive Phase 3 results and is expected to have an NDA submission in the second half of 2026. This acquisition supports Teva's growth strategy by expanding its innovative neuroscience portfolio and addressing a significant unmet medical need. The deal is expected to close by Q3 2026, pending regulatory approval.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
XRP surged about 4% to $1.11 following a broader crypto market rebound triggered by softer U.S. inflation data. Technical signals suggest a bullish inverse head and shoulders pattern, with potential for a 20% price increase if XRP breaks the $1.12–$1...
Revolut has received preliminary approval from Dubai's Virtual Assets Regulatory Authority to offer cryptocurrency services in the UAE, including broker-dealer, asset management, and exchange functions. This approval allows UAE customers to trade and...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
